Skip to main content

Table 2 Migraine-Specific Questionnaire (MSQ) and Medical Outcome Study Short Form 36 (SF-36) baseline scores for the pooled intent-to-treat population

From: The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials

  Baseline Scores (Mean ± SD)
MSQ Domains Placebo (n = 372) Topiramate 100 mg/d (n = 384) p value*
Role Restriction 51.6 ± 16.2 48.1 ± 17.2 0.008
Role Prevention 68.6 ± 18.9 67.0 ± 19.4 0.285
Emotional Function 57.1 ± 22.7 53.7 ± 24.2 0.087
SF-36 Domains Baseline Scores (Mean ± SD)
  Placebo (n = 372) Topiramate 100 mg/d (n = 384) p-value
Physical Functioning 82.0 ± 20.1 82.1 ± 19.4 0.920
Bodily Pain 51.3 ± 22.9 51.5 ± 22.4 0.969
Vitality 51.3 ± 19.4 50.8 ± 20.8 0.891
General Health 68.0 ± 19.5 68.8 ± 20.2 0.593
Role-Emotional 69.0 ± 39.3 70.9 ± 37.7 0.486
Role-Physical 44.5 ± 39.9 44.2 ± 40.8 0.959
Mental Health 70.7 ± 17.7 71.4 ± 16.7 0.483
Social Functioning 68.5 ± 22.3 70.0 ± 23.5 0.331
Physical Component Summary 43.1 ± 8.6 42.9 ± 9.1 0.767
Mental Component Summary 46.9 ± 10.6 47.5 ± 10.2 0.396
  1. *p values are from analysis of variance model with treatment and study as fixed factors.